Advancement in Epilepsy Pharmacotherapy: An Insight into the Pharmacophoric Approaches of Recent Drugs-Reference-Cited by-同舟云学术

Advancement in Epilepsy Pharmacotherapy: An Insight into the Pharmacophoric Approaches of Recent Drugs

Published:2023-12 Issue:3 Volume:23 Page:145-156
ISSN:1871-5249
Container-title:Central Nervous System Agents in Medicinal Chemistry
language:en
Short-container-title:CNSAMC

Author:

Sharma Vikas¹,Kaushik Rahul²,Kumar Verma Krishan²,Gupta Akanksha³,Srivastava Snigdha⁴,Kurmi Rajan Kumar⁴

Affiliation:

1. School of Pharmacy, Sharda University, Plot No. 32-34, K.P.- III, Greater Noida, Uttar Pradesh, 201306, India

2. Metro College of Health Sciences and Research, K.P.- III, Greater Noida, Uttar Pradesh, 201306, India

3. United Institute of Pharmacy, Naini, Prayagraj (Allahabad), Uttar Pradesh, India

4. Ram-Eesh Institute of Vocational and Technical Education. Plot No. 3, K.P.-1, Greater Noida, Uttar Pradesh, 201306, India

Abstract

Abstract: Epilepsy is the most general, extensive, and severe neurological disorder, affecting more than 50 million individuals globally. Initially, conventional medicines and simple salts like potassium bromide were employed as antiepileptic medication candidates. Nowadays, large number of anticonvulsant drugs have been discovered as first-generati, second-generation and newer drugs which are still in development phases. The pharmacophore-based drug design process includes pharmacophore modeling and validation, pharmacophore-based virtual screening, virtual hits profiling, and lead identification with special to epilepsy. This comprehensive article reviews recently developed anticonvulsant derivatives on the basis of pharmacophoric approaches. A literature survey was performed using various search engines like Google Scholar, Scopus, Sci Finder, ScienceDirect, Science gate, Scilit, PubMed, NINDS database of NIH, Bentham Sciences, and other online and print journals and scientific databases for compilation of this review article. The presented review discusses newer drugs that are in the market as well as in various clinical trial phases. Detailed outcomes of pharmacophoric modeling have been discussed for newly derived derivatives like targets involved in Epilepsy, lead molecules etc., for the treatment of epilepsy. This exhaustive review will assist the researchers in the further development of potential antiepileptic agents.

Publisher

Bentham Science Publishers Ltd.

Subject

Molecular Medicine,Neuropsychology and Physiological Psychology,General Neuroscience

Reference102 articles.

1. Jacoby A.; Snape D.; Baker G.; Epilepsy and social identity: The stigma of a chronic neurological disorder. Lancet Neurol 2005,4(3),171-178

2. Savage N.; Epidemiology: The complexities of epilepsy. Nature 2014,511(7508),S2-S3

3. Thompson P.M.; Jahanshad N.; Ching C.R.K.; Salminen L.E.; Thomopoulos S.I.; Bright J.; Baune B.T.; Bertolín S.; Bralten J.; Bruin W.B.; Bülow R.; Chen J.; Chye Y.; Dannlowski U.; de Kovel C.G.F.; Donohoe G.; Eyler L.T.; Faraone S.V.; Favre P.; Filippi C.A.; Frodl T.; Garijo D.; Gil Y.; Grabe H.J.; Grasby K.L.; Hajek T.; Han L.K.M.; Hatton S.N.; Hilbert K.; Ho T.C.; Holleran L.; Homuth G.; Hosten N.; Houenou J.; Ivanov I.; Jia T.; Kelly S.; Klein M.; Kwon J.S.; Laansma M.A.; Leerssen J.; Lueken U.; Nunes A.; Neill J.O.; Opel N.; Piras F.; Piras F.; Postema M.C.; Pozzi E.; Shatokhina N.; Soriano-Mas C.; Spalletta G.; Sun D.; Teumer A.; Tilot A.K.; Tozzi L.; van der Merwe C.; Van Someren E.J.W.; van Wingen G.A.; Völzke H.; Walton E.; Wang L.; Winkler A.M.; Wittfeld K.; Wright M.J.; Yun J.Y.; Zhang G.; Zhang-James Y.; Adhikari B.M.; Agartz I.; Aghajani M.; Aleman A.; Althoff R.R.; Altmann A.; Andreassen O.A.; Baron D.A.; Bartnik-Olson B.L.; Marie Bas-Hoogendam J.; Baskin-Sommers A.R.; Bearden C.E.; Berner L.A.; Boedhoe P.S.W.; Brouwer R.M.; Buitelaar J.K.; Caeyenberghs K.; Cecil C.A.M.; Cohen R.A.; Cole J.H.; Conrod P.J.; De Brito S.A.; de Zwarte S.M.C.; Dennis E.L.; Desrivieres S.; Dima D.; Ehrlich S.; Esopenko C.; Fairchild G.; Fisher S.E.; Fouche J.P.; Francks C.; Frangou S.; Franke B.; Garavan H.P.; Glahn D.C.; Groenewold N.A.; Gurholt T.P.; Gutman B.A.; Hahn T.; Harding I.H.; Hernaus D.; Hibar D.P.; Hillary F.G.; Hoogman M.; Hulshoff Pol H.E.; Jalbrzikowski M.; Karkashadze G.A.; Klapwijk E.T.; Knickmeyer R.C.; Kochunov P.; Koerte I.K.; Kong X.Z.; Liew S.L.; Lin A.P.; Logue M.W.; Luders E.; Macciardi F.; Mackey S.; Mayer A.R.; McDonald C.R.; McMahon A.B.; Medland S.E.; Modinos G.; Morey R.A.; Mueller S.C.; Mukherjee P.; Namazova-Baranova L.; Nir T.M.; Olsen A.; Paschou P.; Pine D.S.; Pizzagalli F.; Rentería M.E.; Rohrer J.D.; Sämann P.G.; Schmaal L.; Schumann G.; Shiroishi M.S.; Sisodiya S.M.; Smit D.J.A.; Sønderby I.E.; Stein D.J.; Stein J.L.; Tahmasian M.; Tate D.F.; Turner J.A.; van den Heuvel O.A.; van der Wee N.J.A.; van der Werf Y.D.; van Erp T.G.M.; van Haren N.E.M.; van Rooij D.; van Velzen L.S.; Veer I.M.; Veltman D.J.; Villalon-Reina J.E.; Walter H.; Whelan C.D.; Wilde E.A.; Zarei M.; Zelman V.; ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries. Transl Psychiatry 2020,10(1),100

4. Kachru R.; Perry-Lunardo C.; Thompson L.A.; CBD use in children—miracle, myth, or mystery? JAMA Pediatr 2021,175(6),652

5. Goodman A.M.; Szaflarski J.P.; Recent advances in neuroimaging of epilepsy. Neurotherapeutics 2021,18(2),811-826